Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Oct 8, 2021 - Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight

Oct 8, 2021

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight

Piramal Enterprises share price fell over 5.5% on the BSE today after the company announced the demerger of its pharmaceuticals business.

A decade after selling its branded formulations business to US-major Abbott Laboratories for US$3.7 bn, the Ajay Piramal group has announced it would demerge its pharmaceutical and financial services arms into separate listed entities.

The pharmaceuticals business will get vertically demerged from Piramal Enterprises and consolidated under Piramal Pharma, the company said in a regulatory filing.

Following the demerger, Piramal Pharma will become one of the large pharma companies listed on NSE and BSE.

In a statement the company said,

  • The board of directors of Piramal Enterprises on 7 October, approved a composite scheme of arrangement providing for the demerger of the pharmaceuticals business from Piramal Enterprises and simplification of the corporate structure to create two industry-focused listed entities in financial services and pharmaceuticals.

Shareholders of Piramal Enterprises (PEL) will get 4 shares of Piramal Pharma for every 1 share in PEL, in addition to their existing holding in PEL.

--- Advertisement ---
Automobile Sector's Colossal Disruption Could Make You a Fortune

During any major disruption in a sector, fortunes are created.

And now, we are at the cusp of a major disruption that the automotive sector will experience.

It is the electric vehicles gold rush.

At Equitymaster, we have unearthed a hidden way to ride the 15x EV opportunity so that you could take home potentially life-changing gains in the long run.

You can get all details of the hidden way in our upcoming special online event.

YES, Register Me for FREE

All you need to know about Piramal Pharma

Piramal Pharma will become a large India-listed pharma company with proven capabilities in contract development and manufacturing, global distribution of complex hospital generics, and a large footprint in the consumer market in India.

Piramal Pharma's contract development and manufacturing (CDMO) business is one of the top three in India and the 13th largest globally.

Its complex hospital generics and India consumer healthcare businesses are well positioned with differentiated products and business models.

CDMO business contributes 62% of the pharma revenues. 29% comes from the hospital generics segment. About 9% comes from India consumer health care.

Last October, when US-based private equity major Carlyle picked up 20% in Piramal Pharma for US$490 m, Nandini Piramal, executive director of Piramal Enterprises (who will now also head the pharma division), said besides paring debt, the fresh equity infusion would be used to create a war-chest for the next phase of growth.

Piramal Pharma carried out three acquisitions in recent months - API maker Hemmo Pharma for Rs 7.8 bn in March, an oral solids dosage facility in Sellersville, Pennsylvania, for about US$17.5 m, and the remaining 49% stake in Convergence Chemicals for Rs 650 m.

Nandini Piramal pointed out the pharma business would continue to grow organically both overseas and in India.

Over the past 10 years, the pharma business has clocked a 14% compound annual growth rate (CAGR) in revenues and 28% CAGR in earnings before interest, tax, depreciation, and amortisation (EBITDA).

Implications of demerger on Piramal Enterprises

Piramal Enterprises is transforming itself from a multi-sector conglomerate structure into two separate sector focused listed entities in financial services and pharmaceuticals.

The demerger is expected to unlock value for PEL shareholders. Both entities will have a leadership positions in their respective sectors.

Currently, PEL owns the financial services business through four investments verticals - housing, finance, lending, alternatives and investment.

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth

Post restructuring, PEL's shareholders will directly own Piramal pharma which will absorb the two subsidiaries, the joint-venture with Allergan, and the overseas subsidiaries.

PEL will absorb the non-banking financial company (NBFC) lending business, the housing finance company, the alternatives business, and investments.

The financial services business contributes Rs 70 bn or 55% of the group's revenues with Pharma contributing the balance 45% (Rs 57.8 bn). The financial services business post-consolidation will have a Rs 650 bn loan book.

Revival phase

The consolidation follows the group's acquisition of Dewan Housing Finance Corporation (DHFL).

Piramal Enterprises will transform into a large listed NBFC with PHL Fininvest Private merging with the parent.

The merged housing finance company, after the DHFL acquisition, will remain a wholly owned subsidiary of Piramal Enterprises.

After a long-drawn battle, Piramal Enterprise completed its acquisition of DHFL by paying Rs 342.5 bn to the lenders. The acquisition will help Piramal diversify its loan book and especially scale up its retail lending book.

Piramal Enterprises has grown multifold with diverse businesses under one listed holding company structure over the years.

The creation of two independent listed entities will empower both to be future-ready and enable them to pursue their own growth strategies with a sharper focus and identity.

How the stock markets reacted to Piramal Enterprises

Shares of Piramal Enterprises opened the day at Rs 2,957.3 on the BSE and Rs 2,931 on the NSE.

Its share price closed at Rs 2,736 (down 5.2%) on the BSE and the NSE.

At its current price, it's trading at a P/E of 63.

The share touched its 52-week high of Rs 3,015 and 52-week low of Rs 1,199 on 5 October 2021 and 29 October 2020, respectively.

Over the last 30 days, the Piramal Enterprises share price is up 4.3%. Over the last one year, the company's share price is up 104%.

About Piramal Enterprises

Piramal Enterprises formerly known as Piramal Healthcare, is the largest company of the Piramal Group.

It's active in business verticals including healthcare, life sciences, information management, and financial services.

Fortune 500 ranked Piramal Healthcare in the top-50 largest corporations across India.

The UN Conference on Trade and Development's World Investment Report 2011 ranked the group among the top 5 pharmaceutical contract manufacturers in the world.

For more details about the company, you can have a look at Piramal Enterprises' factsheet and quarterly results on our website.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight". Click here!


More Views on News

PIRAMAL ENTERPRISES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY22); Net Profit Down 20.0% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (down 20.0% YoY). Sales on the other hand came in at Rs 29 bn (down 1.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

All You Need to Know About Primary and Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 1, 2021 (Close)


  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks